Analysts See $-0.08 EPS for Can-Fite BioPharma Ltd. (CANF)

May 18, 2018 - By Marie Mckinney

Analysts expect Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) to report $-0.08 EPS on May, 29.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.08 EPS. After having $-0.06 EPS previously, Can-Fite BioPharma Ltd.’s analysts see 33.33 % EPS growth. It closed at $1.33 lastly. It is down 23.94% since May 18, 2017 and is downtrending. It has underperformed by 35.49% the S&P500.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company has market cap of $27.29 million. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It currently has negative earnings. It also develops CF102 that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction.

Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.